Key Takeaways
- • Blackstone and TPG have revived acquisition interest in Hologic, a medical diagnostics company, in what could represent one of the largest healthcare take-private deals of 2025, according to sources familiar with the matter.
- • The renewed engagement follows a period of stock price weakness for Hologic, with shares trading at $66 in late September 2025, creating a more attractive entry point for the private equity firms.
- • The acquisition has progressed to completion, with Hologic stockholders receiving $76 per share in cash plus a contingent value right (CVR) of up to $3 per share (payable in two installments of up to $1.50 each), for total consideration of up to $79 per share.
- • Blackstone and TPG's interest in Hologic reflects the firms' strategy of leveraging operational expertise and patient capital to identify efficiency gains and refocus portfolio companies on high-growth segments, particularly in diagnostics.
- • The deal structure demonstrates typical private equity tactics: acquiring undervalued public companies with strong installed bases and operational improvement potential, then executing efficiency initiatives and strategic refocusing post-acquisition.
Summary
Private equity powerhouses Blackstone and TPG revived their interest in acquiring Hologic Inc., a medical diagnostics company, marking a potential return to one of the healthcare sector's most significant take-private transactions. The renewed engagement with Hologic's board occurred in recent weeks and has since progressed to completion, according to multiple sources and SEC filings.
The acquisition reflects a favorable market environment for the private equity sponsors. Hologic shares had declined to $66 per share in late September 2025, providing a lower entry valuation than might have been available during earlier periods. This timing advantage allowed Blackstone and TPG to structure a transaction that ultimately delivered Hologic stockholders $76 per share in cash, alongside a contingent value right (CVR) with potential additional payments of up to $3 per share in two tranches of up to $1.50 each, for total consideration reaching up to $79 per share.
The firms' strategic rationale centers on Hologic's operational characteristics. The company operates with a substantial installed base in diagnostics and possesses meaningful opportunities for operational efficiency gains. By taking the company private, Blackstone and TPG aim to execute a refocusing strategy that emphasizes high-growth diagnostics segments while implementing cost optimization initiatives typical of their operating model. The combination of these factors—coupled with a public market valuation that reflected underperformance—created what the firms identified as an optimal acquisition candidate.
The transaction demonstrates the continued appetite among leading private equity sponsors for healthcare and medtech assets offering clear operational improvement pathways. Blackstone and TPG are known for deploying patient capital and deep operational expertise to complex situations, making Hologic's profile consistent with their investment thesis. The completion of the acquisition, formalized through SEC filings, underscores the deal's progression from initial interest through full execution within the 2025 calendar year.
The acquisition reflects a favorable market environment for the private equity sponsors. Hologic shares had declined to $66 per share in late September 2025, providing a lower entry valuation than might have been available during earlier periods. This timing advantage allowed Blackstone and TPG to structure a transaction that ultimately delivered Hologic stockholders $76 per share in cash, alongside a contingent value right (CVR) with potential additional payments of up to $3 per share in two tranches of up to $1.50 each, for total consideration reaching up to $79 per share.
The firms' strategic rationale centers on Hologic's operational characteristics. The company operates with a substantial installed base in diagnostics and possesses meaningful opportunities for operational efficiency gains. By taking the company private, Blackstone and TPG aim to execute a refocusing strategy that emphasizes high-growth diagnostics segments while implementing cost optimization initiatives typical of their operating model. The combination of these factors—coupled with a public market valuation that reflected underperformance—created what the firms identified as an optimal acquisition candidate.
The transaction demonstrates the continued appetite among leading private equity sponsors for healthcare and medtech assets offering clear operational improvement pathways. Blackstone and TPG are known for deploying patient capital and deep operational expertise to complex situations, making Hologic's profile consistent with their investment thesis. The completion of the acquisition, formalized through SEC filings, underscores the deal's progression from initial interest through full execution within the 2025 calendar year.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.